Want to see GNGBY full AI Analyst Report?
Top Page
Getinge AB
(OTC:GNGBY)
Select Model
Select Model
Rating:70Outperform
Price Target:
$29.00
▲(12.88% Upside)
Action:Reiterated
Date:10/23/26
Overall score reflects solid financial stability and improving profitability/cash flow trends as the biggest positives, supported by a generally positive earnings call and reiterated guidance. The score is tempered by somewhat rich valuation and technical indicators that suggest the stock is near overbought levels, raising near-term volatility risk.
Positive Factors
Recurring and high-margin mix
Recurring revenue at about two-thirds of sales provides a meaningful base of ongoing demand, while the 70% high-margin mix and stronger disposable exposure can support profitability. This should make earnings less dependent on individual capital-equipment projects over the next several quarters.
Negative Factors
Life Science weakness
Continued weakness in washer, isolator and sterilizer products is a durable drag on the Life Science segment, with positive bioprocessing and service performance not fully offsetting declines. Lower volumes also reduce operating leverage, limiting the segment’s contribution to group growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring and high-margin mix
Recurring revenue at about two-thirds of sales provides a meaningful base of ongoing demand, while the 70% high-margin mix and stronger disposable exposure can support profitability. This should make earnings less dependent on individual capital-equipment projects over the next several quarters.
Read all positive factors
Getinge AB (GNGBY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.70B
Dividend Yield1.87%
Average Volume (3M)73.00
Price to Earnings (P/E)26.7
Beta (1Y)0.70
Revenue Growth4.09%
EPS Growth47.73%
CountryUS
Employees12,118
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)10.42
Shares Outstanding254,152,370
10 Day Avg. Volume0
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.02
Price to Sales (P/S)1.70
P/FCF Ratio22.54
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue0.22
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda1.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Getinge AB Business Overview & Revenue Model
Company Description
Getinge AB (publ) is a prominent global medical technology provider, delivering comprehensive products and solutions primarily to operating rooms, intensive care units, and sterilization departments. The company operates through three distinct seg...
How the Company Makes Money
Getinge primarily makes money by selling medical technology equipment and systems, and by generating recurring revenue from services tied to its installed base. A significant portion of revenue comes from capital equipment sales to hospitals and h...
Getinge AB Earnings Call Summary
Earnings Call Date:Oct 21, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jan 26, 2027
Earnings Call Sentiment Positive
The call was predominantly positive. The company reported organic sales and order growth, improved margins, strong free cash flow, a solid balance sheet, record-high customer satisfaction, product-launch momentum and reiterated full-year guidance. These strengths were partly offset by continued Life Science weakness, elevated quality costs, balloon-pump capacity constraints, the surgical perfusion phaseout, regulatory timing and uncertainty around Q4 deliveries, tariffs and geopolitical conditions.Positive Updates
Organic Sales and Order Intake Growth
Third-quarter net sales grew 2.1% organically, with positive development in most business areas, while order intake increased 2.6% organically.
Negative Updates
Life Science Decline in Washer, Isolator and Sterilizer Products
Life Science organic order intake declined slightly because positive performance in bioprocessing and service did not fully offset the continuing decline in the washer, isolator and sterilizer subsegment. Organic net sales also fell slightly, despite robust Sterile Transfer growth.
Read all updates
Q3-2026 Updates
Positive
Negative
Organic Sales and Order Intake Growth
Third-quarter net sales grew 2.1% organically, with positive development in most business areas, while order intake increased 2.6% organically.
Read all positive updates
Company Guidance
Getinge reiterated its expectation for organic net sales growth to be in the range of 3% to 5% for 2026, adjusted for the phaseout of surgical perfusion, which is still expected to have net sales in 2026, declining from about SEK 250 million to SEK 50 million; year-to-date organic growth was 2.5%, and Q4 performance is expected to take the company into the span of 3% to 5%, although the lower part of the guidance span is easier and much more realistic than the upper part. The company’s adjusted EBITA margin was 15.6% on a rolling 12-month basis, 15.8% normalized excluding tariffs, and 14.5% excluding the tariff refund of SEK 381 million in Q2 and Q3 of 2026, versus an adjusted EBITA margin span of 16% to 19% by the end of 2028. Cost release is expected from the second half of this year, mainly impacting 2027 and 2028, while quality-related costs are expected to follow a gradual step down, with the decline definitely larger in '27 compared to '26, and then larger again in 2028; CardioSave’s approval time is still expected to be 6 to 9 months.Getinge AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.46B | 34.97B | 34.76B | 31.83B | 28.29B | 27.05B |
| Gross Profit | 16.49B | 16.65B | 16.15B | 14.49B | 13.41B | 13.58B |
| EBITDA | 6.81B | 6.44B | 5.31B | 5.91B | 5.70B | 6.15B |
| Net Income | 2.83B | 2.26B | 1.64B | 2.41B | 2.49B | 2.97B |
Balance Sheet | ||||||
| Total Assets | 59.60B | 56.51B | 63.92B | 53.52B | 52.03B | 44.55B |
| Cash, Cash Equivalents and Short-Term Investments | 3.19B | 3.40B | 2.96B | 2.73B | 5.68B | 4.08B |
| Total Debt | 11.23B | 10.88B | 10.73B | 8.08B | 5.82B | 4.31B |
| Total Liabilities | 26.89B | 27.01B | 30.71B | 23.18B | 21.58B | 19.38B |
| Stockholders Equity | 33.03B | 29.43B | 33.01B | 30.17B | 30.04B | 24.75B |
Cash Flow | ||||||
| Free Cash Flow | 4.32B | 2.63B | 3.27B | 1.60B | 2.23B | 5.63B |
| Operating Cash Flow | 5.51B | 3.95B | 4.58B | 2.96B | 3.37B | 6.56B |
| Investing Cash Flow | -2.68B | -2.96B | -4.55B | -6.54B | -1.47B | -1.33B |
| Financing Cash Flow | -2.47B | -765.00M | 504.00M | 511.00M | -500.00M | -7.24B |
Getinge AB Technical Analysis
Positive
25.69
Price Trends
25.47
Positive
24.11
Positive
22.55
Positive
Market Momentum
0.73
Negative
83.07
Negative
99.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNGBY, the sentiment is Positive. The current price of 25.69 is below the 20-day moving average (MA) of 26.23, above the 50-day MA of 25.47, and above the 200-day MA of 22.55, indicating a bullish trend. The MACD of 0.73 indicates Negative momentum. The RSI at 83.07 is Negative, neither overbought nor oversold. The STOCH value of 99.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNGBY.
Getinge AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $123.49B | 23.60 | 10.60% | 2.96% | 9.77% | 12.28% | |
74 Outperform | $34.62B | 19.84 | 16.13% | 0.19% | 6.87% | -2.26% | |
70 Outperform | $7.70B | 26.73 | 9.13% | 1.87% | 4.09% | 47.73% | |
70 Outperform | $183.77B | 39.33 | 9.12% | 2.37% | 10.00% | ― | |
67 Neutral | $60.84B | 17.71 | 14.18% | ― | 8.88% | 25.77% | |
65 Neutral | $26.40B | 20.72 | 10.05% | 3.68% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GNGBY
Getinge AB
28.24
5.03
21.67%
ABT
Abbott Laboratories
106.20
-14.42
-11.96%
BSX
Boston Scientific
41.98
-58.74
-58.32%
PHG
Koninklijke Philips
26.92
0.47
1.78%
MDT
Medtronic
96.54
8.75
9.97%
GEHC
GE Healthcare Technologies Inc
76.57
1.77
2.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.